9 New and novel fillers
highlighting elastin and soft tissue augmentation, platelet-rich plasma and a combination of carboxymethyl cellulose (CMC), and polyethylene oxide (PEO)
Summary and Key Features
• Dermal elastin confers on tissue the ability to stretch and recoil and is important in cutaneous support
• Elastin may be a useful tissue filler and attempts to regenerate elastin are currently underway using recombinant tropoelastin
• Hyaluronic acid may be used as the crosslinking agent for tropoelastin and is being trialled in this form as a cutaneous filling agent
• Platelet rich plasma is a platelet rich concentrate in a small volume of plasma
• Platelets are a rich source of at least 7 growth factors including transforming vasoactive and epithelial factors
• Simplified methods have allowed harvesting of platelets and separation from other blood cells without lysing of the platelets
• Platelet rich plasma may have roles both in topical wound healing and in injected approaches as an augmentation and tissue regenerative agent.
• Platelet rich plasma has been shown to induce neocollagenesis, neovascularization and neolipogenesis after injection
• A novel filler comprising carboxymethyl cellulose and polyetheleneoxide (Laresse) has been used as a tissue filler
• Laresse has been compared favourably to Restylane in a short term study
• Laresse has been injected into upper lips, nasolabial and melomental folds in a small cohort of patients with few adverse reactions
Elastin and soft tissue augmentation
The raisons d’être of elastin regeneration and injecting elastin products
Damaged elastic fibers are responsible for an aged and wrinkled appearance (Fig. 9.1). Given the importance of elastin to the skin and its loss in the aging process, it is not surprising that various attempts have been made to maintain or replenish elastin levels. Treatments aiming to repair or regenerate elastin in elastic tissues should consider all the molecules implicated in elastin fiber formation. However, as elastin fibers develop, they ultimately consist of over 90% elastin and so the integration of sufficient tropoelastin into elastin fibers is clearly the major target. Effective treatment approaches are restricted owing to the obvious physical challenge of transferring materials and / or treatments across the epidermis and into the dermis, resulting in a preference for small molecules and physical treatments. Tretinoin or all-trans retinoic acid is a small molecule utilized for many years in topical formulations to increase elastin production through increased tropoelastin and fibrillin expression and secretion. Molecules such as aldosterone and mineralocorticoid receptor antagonists may impact on elastin fiber deposition in skin. Soy and rice (USPTO 19469891) extracts may also increase elastin formation, as can a combination of zinc and copper. More recently, a dill extract has also been shown by Cenizo et al to have the potential to promote elastin formation by promoting LOXL synthesis and secretion into the dermis.
Courtesy of Hu Q, Reymond JL, Pinel N, et al 2006 Inflammatory destruction of elastic fibers in acquired cutis laxa is associated with missense alleles in the elastin and fibulin-5 genes. Journal of Investigative Dermatology 126(2):283-290.
A new approach to treat aged and damaged skin using elastin is currently in clinical development in Australia by Elastagen Pty Ltd. The approach is unique to skin augmentation treatments in that it is based on a recombinant human tropoelastin protein, which is identical to the one naturally occurring in healthy human skin. As seen in early clinical studies, this high degree of similarity to the natural elastin protein promises a significantly higher level of tissue compatibility than achieved with animal-derived products or synthetic polymer materials (Fig. 9.2). The treatment process, trademarked as elastatherapy®, also benefits from a new formulation chemistry that enables the tropoelastin protein to be cross-linked with a low-concentration HA component. There is no requirement for the toxic cross-linking agents often used in other products and the use of hyaluronidase to correct poor treatment outcomes is still an option – a significant advantage over alternative dermal filler materials. Elastin treatments benefit from the cell-supporting properties of elastin and the potential to stimulate skin cells, leading to the formation of new collagen at the treatment site. This latter property coupled with the product’s smooth, cohesive structure may present significant advantages over particulate products, which target collagen regeneration but carry a significant risk of lumps and nodules. The product range also includes the potential to bulk the skin with a long-lasting, highly biocompatible elastin material and the unique prospect of restoring elastin to improve the skin’s physical properties and suppleness.